

Figure 1




Figure 2




Figure 3

Clinicopathologic features and outcome of 12 consecutive patients with relapsed acute promyelocytic leukemia treated with oral As₂O₃

sex / age status	previous induction treatment	Time from last CR			Oral As ₂ O ₃ therapy duration additional PCR result			Consolidation	Latest PCR ¹	DFS	Remarks
		Hb	WBC	Plat	duration	additional PCR					
1* M/23 R1	ATRA + Dauno i.v. As ₂ O ₃ + Ida	11 m	15.6	2.1	87	59 d	Ida	CR	Ida	13 m	
2* M/33 R2	Dauno / i.v. As ₂ O ₃ + Ida	10 m	14.0	2.5	25	76 d	ATRA	NR	+ (dead)	19 m +	
3* F/13 R2	ATRA + i.v. As ₂ O ₃	25 m	13.4	2.1	20	32 d	ATRA	CR	As ₂ O ₃ + ATRA	- (18 m)	
4 M/54 R1	ATRA + Dauno	12 m	8.6	1.2	15	30 d	ATRA	CR	As ₂ O ₃ + ATRA	- (18 m)	
5* M/32 R1	ATRA + Dauno + MP	100 m	8.5	34.8	81	40 d	Ida	CR	Ida	- (18 m)	mother: AML
6 F/32 R1	ATRA + Dauno	22 m	14.5	2.4	177	33 d	-	CR	Ida	- (18 m)	
7* F/45 R2	ATRA + Dauno / i.v. As ₂ O ₃ + Ida	12 m	12.2	0.8	84	51 d	-	CR	Ida	- (12 m)	
8 F/65 R1	ATRA	17 m	11.2	1.9	50	37 d	ATRA	CR	As ₂ O ₃ + ATRA	- (14 m)	
9 F/18 R2	ATRA + Dauno / i.v. As ₂ O ₃ + Ida	16 m	7.2	2.8	141	28 d	-	CR	As ₂ O ₃ + ATRA	- (12 m)	15 m + CRF due to DM on CAPD, Ida consolidation omitted due to CRF
10* F/18 R1	ATRA + Dauno	12 m	10.1	1.9	180	28 d	ATRA	CR	As ₂ O ₃ + ATRA	- (12 m)	14 m +
11* M/45 R1	ATRA + Dauno	240 m	4.2	0.6	9	22 d	-	CR	Ida	- (6 m)	
								CR	As ₂ O ₃	- (3 m)	7 m + Ida consolidation omitted due to high cumulative doses of anthracycline
12 F/40 R1	ATRA + Ara-c	23 m	8.5	6.5	39	26 d	Ida	CR	Ida	- (3 m)	6 m + CRHD, double valve rep

^{*}: pharmacokinetic data of oral As₂O₃ have previously been reported⁶

1: PCR for PML/RARA, +: positive, -: negative, (time from initial diagnosis)

M: male; F: female, CR: complete remission; NR: non-remission; R1: first relapse; R2: second relapse

CBC: complete blood count; Hb: hemoglobin (g/dL); WBC: white blood cell count ($\times 10^9/L$); Plat: platelet count ($\times 10^9/L$)

m: months; d: days; DFS: disease free survival

ATRA: all-trans retinoic acid; Dauno: daunorubicin; Ida: idarubicin; Ara-c: cytosine arabinoside

CA: carcinoma; AML: acute myeloid leukemia; CRF: chronic renal failure; DM: diabetes mellitus

CAPD: continuous ambulatory peritoneal dialysis; CRHD: chronic rheumatic heart disease; rep: replacement